{
    "info": {
        "nct_id": "NCT04876248",
        "official_title": "Phase 2 Trial of Belantamab Mafodotin Consolidation Treatment in Patients With Multiple Myeloma and MRD Positivity After Autologous Stem Cell Transplantation",
        "inclusion_criteria": "* Age >= 18 years of age at time of consent\n* Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2\n* Histologically or cytologically confirmed diagnosis of multiple myeloma (MM) as defined according to International Myeloma Working Group (IMWG), 2016 criteria, and\n\n  * Patient is considered transplant eligible, and\n  * Is not MRD negative complete response (CR) after high dose chemotherapy\n* Absolute neutrophil count (ANC) >= 1.5 X 10^9/L (within 14 days of first dose of study treatment)\n* Hemoglobin >= 8.0 g/dL (within 14 days of first dose of study treatment)\n* Platelets >= 75 X 10^9/L (within 14 days of first dose of study treatment)\n* Total bilirubin =< 1.5 X upper limit of normal (ULN) (isolated bilirubin >= 1.5 x ULN is acceptable if bilirubin is fractionated and direct bilirubin < 35%) (within 14 days of first dose of study treatment)\n* Alanine aminotransferase (ALT) =< 2.5 X ULN or < 5 times ULN if documented liver infiltration (within 14 days of first dose of study treatment)\n* Estimated glomerular filtration rate (eGFR) >= 30 mL/min/ 1.73 m^2 (within 14 days of first dose of study treatment)\n* Spot urine (albumin/creatinine ratios (spot urine) < 500 mg/g (56 mg/mmol) OR urine dipstick Negative/trace (if >= 1+ only eligible if confirmed =< 500 mg/g (56 mg/mmol) by albumin/creatinine ratio (spot urine from first void) (within 14 days of first dose of study treatment)\n* A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:\n\n  * Not a woman of childbearing potential (WOCBP) OR\n  * A WOCBP who agrees to follow the contraceptive guidance during the treatment period and for at least 4 months after the last dose of study intervention and agrees not to donate eggs (ova, oocytes) for the purpose of reproduction during this period\n* Female participants of childbearing potential are to have a negative serum pregnancy test within 24 hours before the first dose of study intervention\n* A male participant must agree to use an adequate method of contraception (as described below) during the treatment period and for at least 6 months after the last dose of study treatment to allow for clearance of any altered sperm, along with the following:\n\n  * Refrain from donating sperm PLUS either:\n\n    * Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent. OR\n    * Must agree to use contraception/barrier\n* All prior treatment-related toxicities (defined by National Cancer Institute- Common Toxicity Criteria for Adverse Events (NCI-CTCAE), version 5.0) must be =< grade 1 at the time of enrolment except for alopecia\n* Participant must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Evidence of active bleeding requiring intervention within the last four weeks prior to first dose of study treatment\n* Current corneal epithelial disease except mild changes in corneal epithelium\n* Any major surgery within the last four weeks of first dose of study treatment\n* Use of contact lenses while participating in this study\n* Participant must not have had plasmapheresis within 7 days prior to first dose of study treatment\n* Presence of active renal condition (infection, requirement for dialysis or any other condition that could affect patient's safety). Patients with isolated proteinuria resulting from MM are eligible\n* Any serious and/or unstable pre-existing medical, psychiatric disorder or other conditions (including lab abnormalities) that could interfere with patient's safety or compliance to the study procedures\n* Current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice, or cirrhosis. Note: Stable chronic liver disease (including Gilbert's syndrome or asymptomatic gallstones) or hepatobiliary involvement of malignancy is acceptable if patient otherwise meets entry criteria\n* Malignancies other than disease under study, unless the second malignancy has been medically stable for at least 2 years and, in the opinion of the principal investigators, will not affect the evaluation of the effects of clinical trial treatments on the currently targeted malignancy. Participants with curatively treated non-melanoma skin cancer may be enrolled without a 2-year restriction\n* Evidence of cardiovascular risk including any of the following:\n\n  * Evidence of current clinically significant uncontrolled arrhythmias, including clinically significant electrocardiography (EKG) abnormalities such as 2nd degree (type II) or 3rd degree atrioventricular (AV) block.\n  * History of myocardial infarction, acute coronary syndromes (including unstable angina), coronary angioplasty, or stenting or bypass grafting within two months of first dose.\n  * Class III or IV heart failure as defined by the New York Heart Association functional classification system.\n  * Uncontrolled hypertension\n* Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to belantamab mafodotin or lenalidomide\n* Active infection requiring antibiotic, antiviral, or antifungal treatment\n* Known human immunodeficiency virus (HIV) infection\n* Presence of hepatitis B surface antigen (HBsAg), at or within 3 months of registration Note: If Hepatitis B core antibody (HBcAb) present, see additional monitoring recommendations\n* Positive hepatitis C antibody test result or positive hepatitis C ribonucleic acid (RNA) test result at or within 3 months prior registration. Note: Patients with positive hepatitis C antibody due to prior resolved disease can be eligible, only if a confirmatory negative hepatitis C RNA test is obtained.\n\n  * Note: Hepatitis RNA testing is optional and patients with negative hepatitis C antibody test are not required to also undergo hepatitis C RNA testing\n* Best corrected visual acuity in the worst seeing eye worse than 20/100 (Snellen equivalent). Participants with vision worse than 20/100 due to a treatable condition (e.g., cataract) may be considered on an individual case basis within 6 months before registration\n* Use of an investigational drug within 14 days of first dose of study treatment or five half-lives, whichever is shorter, preceding the first dose of study drug. Prior treatment with a monoclonal antibody within 30 days of first dose of study treatment\n* Previously progressed on treatment with belantamab mafodotin\n* Pregnant or lactating female participants\n* Unwilling or unable to follow protocol requirements\n* Any condition which in the investigator's opinion deems the participant an unsuitable candidate to receive study drug",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Must agree to use contraception/barrier",
            "criterions": [
                {
                    "exact_snippets": "Must agree to use contraception/barrier",
                    "criterion": "contraception/barrier use",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent. OR",
            "criterions": [
                {
                    "exact_snippets": "Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent.",
                    "criterion": "abstinence from heterosexual intercourse",
                    "requirements": [
                        {
                            "requirement_type": "lifestyle_preference",
                            "expected_value": "abstinent from heterosexual intercourse as preferred and usual lifestyle"
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": "long term and persistent basis"
                        },
                        {
                            "requirement_type": "agreement_to_remain_abstinent",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status of 0-2",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:",
            "criterions": [
                {
                    "exact_snippets": "female participant",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "female"
                        }
                    ]
                },
                {
                    "exact_snippets": "not pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "pregnant",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "not breastfeeding",
                    "criterion": "breastfeeding status",
                    "requirements": [
                        {
                            "requirement_type": "breastfeeding",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Estimated glomerular filtration rate (eGFR) >= 30 mL/min/ 1.73 m^2 (within 14 days of first dose of study treatment)",
            "criterions": [
                {
                    "exact_snippets": "Estimated glomerular filtration rate (eGFR) >= 30 mL/min/ 1.73 m^2 (within 14 days of first dose of study treatment)",
                    "criterion": "estimated glomerular filtration rate (eGFR)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "mL/min/1.73 m^2"
                            }
                        },
                        {
                            "requirement_type": "timeframe",
                            "expected_value": "within 14 days of first dose of study treatment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participant must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure",
            "criterions": [
                {
                    "exact_snippets": "Participant must understand the investigational nature of this study",
                    "criterion": "understanding of investigational nature of study",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure",
                    "criterion": "signed informed consent form",
                    "requirements": [
                        {
                            "requirement_type": "signed",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "approval",
                            "expected_value": [
                                "Independent Ethics Committee",
                                "Institutional Review Board"
                            ]
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "prior to receiving any study related procedure"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* A male participant must agree to use an adequate method of contraception (as described below) during the treatment period and for at least 6 months after the last dose of study treatment to allow for clearance of any altered sperm, along with the following:",
            "criterions": [
                {
                    "exact_snippets": "A male participant must agree to use an adequate method of contraception (as described below) during the treatment period and for at least 6 months after the last dose of study treatment",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "agreement",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "method adequacy",
                            "expected_value": "adequate method of contraception"
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "A male participant",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "male"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Is not MRD negative complete response (CR) after high dose chemotherapy",
            "criterions": [
                {
                    "exact_snippets": "Is not MRD negative complete response (CR) after high dose chemotherapy",
                    "criterion": "MRD negative complete response after high dose chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* All prior treatment-related toxicities (defined by National Cancer Institute- Common Toxicity Criteria for Adverse Events (NCI-CTCAE), version 5.0) must be =< grade 1 at the time of enrolment except for alopecia",
            "criterions": [
                {
                    "exact_snippets": "All prior treatment-related toxicities ... must be =< grade 1 at the time of enrolment except for alopecia",
                    "criterion": "prior treatment-related toxicities",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "grade (NCI-CTCAE v5.0)"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "except for alopecia",
                    "criterion": "alopecia",
                    "requirements": [
                        {
                            "requirement_type": "exemption",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Refrain from donating sperm PLUS either:",
            "criterions": [
                {
                    "exact_snippets": "Refrain from donating sperm",
                    "criterion": "sperm donation",
                    "requirements": [
                        {
                            "requirement_type": "refrain",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Alanine aminotransferase (ALT) =< 2.5 X ULN or < 5 times ULN if documented liver infiltration (within 14 days of first dose of study treatment)",
            "criterions": [
                {
                    "exact_snippets": "Alanine aminotransferase (ALT) =< 2.5 X ULN",
                    "criterion": "alanine aminotransferase (ALT) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.5,
                                "unit": "X ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "< 5 times ULN if documented liver infiltration",
                    "criterion": "alanine aminotransferase (ALT) level with documented liver infiltration",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 5,
                                "unit": "X ULN"
                            }
                        },
                        {
                            "requirement_type": "condition",
                            "expected_value": "documented liver infiltration"
                        }
                    ]
                },
                {
                    "exact_snippets": "within 14 days of first dose of study treatment",
                    "criterion": "timing of ALT measurement",
                    "requirements": [
                        {
                            "requirement_type": "time window",
                            "expected_value": "within 14 days of first dose of study treatment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Age >= 18 years of age at time of consent",
            "criterions": [
                {
                    "exact_snippets": "Age >= 18 years of age at time of consent",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hemoglobin >= 8.0 g/dL (within 14 days of first dose of study treatment)",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobin >= 8.0 g/dL",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 8.0,
                                "unit": "g/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Female participants of childbearing potential are to have a negative serum pregnancy test within 24 hours before the first dose of study intervention",
            "criterions": [
                {
                    "exact_snippets": "Female participants of childbearing potential",
                    "criterion": "sex and childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        },
                        {
                            "requirement_type": "childbearing potential",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "negative serum pregnancy test within 24 hours before the first dose of study intervention",
                    "criterion": "serum pregnancy test",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "within 24 hours before the first dose of study intervention"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histologically or cytologically confirmed diagnosis of multiple myeloma (MM) as defined according to International Myeloma Working Group (IMWG), 2016 criteria, and",
            "criterions": [
                {
                    "exact_snippets": "Histologically or cytologically confirmed diagnosis of multiple myeloma (MM)",
                    "criterion": "multiple myeloma diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "histologically",
                                "cytologically"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "as defined according to International Myeloma Working Group (IMWG), 2016 criteria",
                    "criterion": "multiple myeloma diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "diagnostic criteria",
                            "expected_value": "International Myeloma Working Group (IMWG), 2016 criteria"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* A WOCBP who agrees to follow the contraceptive guidance during the treatment period and for at least 4 months after the last dose of study intervention and agrees not to donate eggs (ova, oocytes) for the purpose of reproduction during this period",
            "criterions": [
                {
                    "exact_snippets": "A WOCBP",
                    "criterion": "woman of childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "agrees to follow the contraceptive guidance during the treatment period and for at least 4 months after the last dose of study intervention",
                    "criterion": "contraceptive guidance adherence",
                    "requirements": [
                        {
                            "requirement_type": "adherence_duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 4,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "agrees not to donate eggs (ova, oocytes) for the purpose of reproduction during this period",
                    "criterion": "egg donation",
                    "requirements": [
                        {
                            "requirement_type": "donation",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient is considered transplant eligible, and",
            "criterions": [
                {
                    "exact_snippets": "Patient is considered transplant eligible",
                    "criterion": "transplant eligibility",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Spot urine (albumin/creatinine ratios (spot urine) < 500 mg/g (56 mg/mmol) OR urine dipstick Negative/trace (if >= 1+ only eligible if confirmed =< 500 mg/g (56 mg/mmol) by albumin/creatinine ratio (spot urine from first void) (within 14 days of first dose of study treatment)",
            "criterions": [
                {
                    "exact_snippets": "Spot urine (albumin/creatinine ratios (spot urine) < 500 mg/g (56 mg/mmol)",
                    "criterion": "spot urine albumin/creatinine ratio",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 500,
                                "unit": "mg/g"
                            }
                        },
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 56,
                                "unit": "mg/mmol"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "urine dipstick Negative/trace (if >= 1+ only eligible if confirmed =< 500 mg/g (56 mg/mmol) by albumin/creatinine ratio (spot urine from first void) (within 14 days of first dose of study treatment)",
                    "criterion": "urine dipstick result",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": [
                                "Negative",
                                "trace"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "if >= 1+ only eligible if confirmed =< 500 mg/g (56 mg/mmol) by albumin/creatinine ratio (spot urine from first void) (within 14 days of first dose of study treatment)",
                    "criterion": "spot urine albumin/creatinine ratio (confirmation for urine dipstick >= 1+)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 500,
                                "unit": "mg/g"
                            }
                        },
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 56,
                                "unit": "mg/mmol"
                            }
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "within 14 days of first dose of study treatment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Not a woman of childbearing potential (WOCBP) OR",
            "criterions": [
                {
                    "exact_snippets": "Not a woman of childbearing potential (WOCBP)",
                    "criterion": "woman of childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Platelets >= 75 X 10^9/L (within 14 days of first dose of study treatment)",
            "criterions": [
                {
                    "exact_snippets": "Platelets >= 75 X 10^9/L (within 14 days of first dose of study treatment)",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 75,
                                "unit": "X 10^9/L"
                            }
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "within 14 days of first dose of study treatment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Total bilirubin =< 1.5 X upper limit of normal (ULN) (isolated bilirubin >= 1.5 x ULN is acceptable if bilirubin is fractionated and direct bilirubin < 35%) (within 14 days of first dose of study treatment)",
            "criterions": [
                {
                    "exact_snippets": "Total bilirubin =< 1.5 X upper limit of normal (ULN)",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "isolated bilirubin >= 1.5 x ULN is acceptable if bilirubin is fractionated and direct bilirubin < 35%",
                    "criterion": "direct bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 35,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Absolute neutrophil count (ANC) >= 1.5 X 10^9/L (within 14 days of first dose of study treatment)",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count (ANC) >= 1.5 X 10^9/L (within 14 days of first dose of study treatment)",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1.5,
                                "unit": "X 10^9/L"
                            }
                        },
                        {
                            "requirement_type": "timeframe",
                            "expected_value": "within 14 days of first dose of study treatment"
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Previously progressed on treatment with belantamab mafodotin",
            "criterions": [
                {
                    "exact_snippets": "Previously progressed on treatment with belantamab mafodotin",
                    "criterion": "progression on belantamab mafodotin treatment",
                    "requirements": [
                        {
                            "requirement_type": "history of progression",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment agent",
                            "expected_value": "belantamab mafodotin"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Class III or IV heart failure as defined by the New York Heart Association functional classification system.",
            "criterions": [
                {
                    "exact_snippets": "Class III or IV heart failure as defined by the New York Heart Association functional classification system.",
                    "criterion": "heart failure (New York Heart Association functional classification)",
                    "requirements": [
                        {
                            "requirement_type": "class",
                            "expected_value": [
                                "III",
                                "IV"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Uncontrolled hypertension",
            "criterions": [
                {
                    "exact_snippets": "Uncontrolled hypertension",
                    "criterion": "hypertension",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Best corrected visual acuity in the worst seeing eye worse than 20/100 (Snellen equivalent). Participants with vision worse than 20/100 due to a treatable condition (e.g., cataract) may be considered on an individual case basis within 6 months before registration",
            "criterions": [
                {
                    "exact_snippets": "Best corrected visual acuity in the worst seeing eye worse than 20/100 (Snellen equivalent)",
                    "criterion": "best corrected visual acuity in the worst seeing eye",
                    "requirements": [
                        {
                            "requirement_type": "visual acuity",
                            "expected_value": {
                                "operator": "<",
                                "value": 20,
                                "unit": "/100 (Snellen equivalent)"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Participants with vision worse than 20/100 due to a treatable condition (e.g., cataract) may be considered on an individual case basis within 6 months before registration",
                    "criterion": "vision worse than 20/100 due to a treatable condition",
                    "requirements": [
                        {
                            "requirement_type": "visual acuity",
                            "expected_value": {
                                "operator": "<",
                                "value": 20,
                                "unit": "/100"
                            }
                        },
                        {
                            "requirement_type": "cause",
                            "expected_value": "treatable condition"
                        },
                        {
                            "requirement_type": "consideration period",
                            "expected_value": "within 6 months before registration"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any major surgery within the last four weeks of first dose of study treatment",
            "criterions": [
                {
                    "exact_snippets": "Any major surgery within the last four weeks of first dose of study treatment",
                    "criterion": "major surgery",
                    "requirements": [
                        {
                            "requirement_type": "time since surgery",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known human immunodeficiency virus (HIV) infection",
            "criterions": [
                {
                    "exact_snippets": "Known human immunodeficiency virus (HIV) infection",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "awareness/status",
                            "expected_value": "known"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to belantamab mafodotin or lenalidomide",
            "criterions": [
                {
                    "exact_snippets": "Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to belantamab mafodotin",
                    "criterion": "hypersensitivity or idiosyncrasy to drugs chemically related to belantamab mafodotin",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to ... lenalidomide",
                    "criterion": "hypersensitivity or idiosyncrasy to drugs chemically related to lenalidomide",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Presence of active renal condition (infection, requirement for dialysis or any other condition that could affect patient's safety). Patients with isolated proteinuria resulting from MM are eligible",
            "criterions": [
                {
                    "exact_snippets": "Presence of active renal condition (infection, requirement for dialysis or any other condition that could affect patient's safety)",
                    "criterion": "active renal condition",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "infection",
                    "criterion": "renal infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "requirement for dialysis",
                    "criterion": "requirement for dialysis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "any other condition that could affect patient's safety",
                    "criterion": "renal condition affecting patient's safety",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients with isolated proteinuria resulting from MM are eligible",
                    "criterion": "isolated proteinuria resulting from MM",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Evidence of cardiovascular risk including any of the following:",
            "criterions": [
                {
                    "exact_snippets": "Evidence of cardiovascular risk",
                    "criterion": "cardiovascular risk",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Unwilling or unable to follow protocol requirements",
            "criterions": [
                {
                    "exact_snippets": "Unwilling or unable to follow protocol requirements",
                    "criterion": "willingness and ability to follow protocol requirements",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of myocardial infarction, acute coronary syndromes (including unstable angina), coronary angioplasty, or stenting or bypass grafting within two months of first dose.",
            "criterions": [
                {
                    "exact_snippets": "History of myocardial infarction ... within two months of first dose.",
                    "criterion": "myocardial infarction",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "acute coronary syndromes (including unstable angina) ... within two months of first dose.",
                    "criterion": "acute coronary syndromes (including unstable angina)",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "coronary angioplasty ... within two months of first dose.",
                    "criterion": "coronary angioplasty",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "stenting ... within two months of first dose.",
                    "criterion": "stenting",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "bypass grafting within two months of first dose.",
                    "criterion": "bypass grafting",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Use of an investigational drug within 14 days of first dose of study treatment or five half-lives, whichever is shorter, preceding the first dose of study drug. Prior treatment with a monoclonal antibody within 30 days of first dose of study treatment",
            "criterions": [
                {
                    "exact_snippets": "Use of an investigational drug within 14 days of first dose of study treatment or five half-lives, whichever is shorter, preceding the first dose of study drug",
                    "criterion": "use of investigational drug",
                    "requirements": [
                        {
                            "requirement_type": "time since last use",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 14,
                                        "unit": "days"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "five half-lives"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior treatment with a monoclonal antibody within 30 days of first dose of study treatment",
                    "criterion": "prior treatment with monoclonal antibody",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active infection requiring antibiotic, antiviral, or antifungal treatment",
            "criterions": [
                {
                    "exact_snippets": "Active infection requiring antibiotic, antiviral, or antifungal treatment",
                    "criterion": "active infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "requires antimicrobial treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any serious and/or unstable pre-existing medical, psychiatric disorder or other conditions (including lab abnormalities) that could interfere with patient's safety or compliance to the study procedures",
            "criterions": [
                {
                    "exact_snippets": "serious and/or unstable pre-existing medical ... disorder",
                    "criterion": "pre-existing medical disorder",
                    "requirements": [
                        {
                            "requirement_type": "seriousness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "stability",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "serious and/or unstable pre-existing ... psychiatric disorder",
                    "criterion": "pre-existing psychiatric disorder",
                    "requirements": [
                        {
                            "requirement_type": "seriousness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "stability",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "other conditions (including lab abnormalities) that could interfere with patient's safety or compliance to the study procedures",
                    "criterion": "other conditions (including lab abnormalities)",
                    "requirements": [
                        {
                            "requirement_type": "potential to interfere with safety or compliance",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Use of contact lenses while participating in this study",
            "criterions": [
                {
                    "exact_snippets": "Use of contact lenses while participating in this study",
                    "criterion": "use of contact lenses",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Malignancies other than disease under study, unless the second malignancy has been medically stable for at least 2 years and, in the opinion of the principal investigators, will not affect the evaluation of the effects of clinical trial treatments on the currently targeted malignancy. Participants with curatively treated non-melanoma skin cancer may be enrolled without a 2-year restriction",
            "criterions": [
                {
                    "exact_snippets": "Malignancies other than disease under study, unless the second malignancy has been medically stable for at least 2 years",
                    "criterion": "second malignancy",
                    "requirements": [
                        {
                            "requirement_type": "medical stability duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "in the opinion of the principal investigators, will not affect the evaluation of the effects of clinical trial treatments on the currently targeted malignancy",
                    "criterion": "second malignancy",
                    "requirements": [
                        {
                            "requirement_type": "impact on evaluation of trial treatments",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Participants with curatively treated non-melanoma skin cancer may be enrolled without a 2-year restriction",
                    "criterion": "curatively treated non-melanoma skin cancer",
                    "requirements": [
                        {
                            "requirement_type": "history of curative treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Presence of hepatitis B surface antigen (HBsAg), at or within 3 months of registration Note: If Hepatitis B core antibody (HBcAb) present, see additional monitoring recommendations",
            "criterions": [
                {
                    "exact_snippets": "Presence of hepatitis B surface antigen (HBsAg), at or within 3 months of registration",
                    "criterion": "hepatitis B surface antigen (HBsAg)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "If Hepatitis B core antibody (HBcAb) present",
                    "criterion": "Hepatitis B core antibody (HBcAb)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Evidence of active bleeding requiring intervention within the last four weeks prior to first dose of study treatment",
            "criterions": [
                {
                    "exact_snippets": "Evidence of active bleeding requiring intervention within the last four weeks prior to first dose of study treatment",
                    "criterion": "active bleeding requiring intervention",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks prior to first dose of study treatment"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Positive hepatitis C antibody test result or positive hepatitis C ribonucleic acid (RNA) test result at or within 3 months prior registration. Note: Patients with positive hepatitis C antibody due to prior resolved disease can be eligible, only if a confirmatory negative hepatitis C RNA test is obtained.",
            "criterions": [
                {
                    "exact_snippets": "Positive hepatitis C antibody test result or positive hepatitis C ribonucleic acid (RNA) test result at or within 3 months prior registration",
                    "criterion": "hepatitis C infection status",
                    "requirements": [
                        {
                            "requirement_type": "test result",
                            "expected_value": [
                                "positive hepatitis C antibody",
                                "positive hepatitis C RNA"
                            ]
                        },
                        {
                            "requirement_type": "test timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "months prior to registration"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients with positive hepatitis C antibody due to prior resolved disease can be eligible, only if a confirmatory negative hepatitis C RNA test is obtained",
                    "criterion": "hepatitis C infection status (resolved)",
                    "requirements": [
                        {
                            "requirement_type": "antibody test result",
                            "expected_value": "positive"
                        },
                        {
                            "requirement_type": "disease status",
                            "expected_value": "prior resolved"
                        },
                        {
                            "requirement_type": "confirmatory RNA test result",
                            "expected_value": "negative"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any condition which in the investigator's opinion deems the participant an unsuitable candidate to receive study drug",
            "criterions": [
                {
                    "exact_snippets": "Any condition which in the investigator's opinion deems the participant an unsuitable candidate to receive study drug",
                    "criterion": "any condition deemed unsuitable by investigator",
                    "requirements": [
                        {
                            "requirement_type": "investigator judgment",
                            "expected_value": "deems participant unsuitable to receive study drug"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Note: Hepatitis RNA testing is optional and patients with negative hepatitis C antibody test are not required to also undergo hepatitis C RNA testing",
            "criterions": [
                {
                    "exact_snippets": "Hepatitis RNA testing is optional",
                    "criterion": "hepatitis RNA testing",
                    "requirements": [
                        {
                            "requirement_type": "requirement",
                            "expected_value": "optional"
                        }
                    ]
                },
                {
                    "exact_snippets": "patients with negative hepatitis C antibody test are not required to also undergo hepatitis C RNA testing",
                    "criterion": "hepatitis C RNA testing",
                    "requirements": [
                        {
                            "requirement_type": "requirement",
                            "expected_value": "not required if hepatitis C antibody test is negative"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participant must not have had plasmapheresis within 7 days prior to first dose of study treatment",
            "criterions": [
                {
                    "exact_snippets": "must not have had plasmapheresis within 7 days prior to first dose of study treatment",
                    "criterion": "plasmapheresis",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": ">",
                                "value": 7,
                                "unit": "days prior to first dose of study treatment"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Current corneal epithelial disease except mild changes in corneal epithelium",
            "criterions": [
                {
                    "exact_snippets": "Current corneal epithelial disease except mild changes in corneal epithelium",
                    "criterion": "corneal epithelial disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "exception",
                            "expected_value": "mild changes in corneal epithelium"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pregnant or lactating female participants",
            "criterions": [
                {
                    "exact_snippets": "Pregnant ... female participants",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "pregnancy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "lactating female participants",
                    "criterion": "lactation status",
                    "requirements": [
                        {
                            "requirement_type": "lactation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice, or cirrhosis. Note: Stable chronic liver disease (including Gilbert's syndrome or asymptomatic gallstones) or hepatobiliary involvement of malignancy is acceptable if patient otherwise meets entry criteria",
            "criterions": [
                {
                    "exact_snippets": "Current unstable liver or biliary disease per investigator assessment",
                    "criterion": "liver or biliary disease",
                    "requirements": [
                        {
                            "requirement_type": "stability",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "presence of ascites",
                    "criterion": "ascites",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "presence of ... encephalopathy",
                    "criterion": "encephalopathy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "presence of ... coagulopathy",
                    "criterion": "coagulopathy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "presence of ... hypoalbuminemia",
                    "criterion": "hypoalbuminemia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "presence of ... esophageal or gastric varices",
                    "criterion": "esophageal or gastric varices",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "presence of ... persistent jaundice",
                    "criterion": "persistent jaundice",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "presence of ... cirrhosis",
                    "criterion": "cirrhosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Evidence of current clinically significant uncontrolled arrhythmias, including clinically significant electrocardiography (EKG) abnormalities such as 2nd degree (type II) or 3rd degree atrioventricular (AV) block.",
            "criterions": [
                {
                    "exact_snippets": "Evidence of current clinically significant uncontrolled arrhythmias",
                    "criterion": "arrhythmias",
                    "requirements": [
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "current",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "clinically significant electrocardiography (EKG) abnormalities such as 2nd degree (type II) or 3rd degree atrioventricular (AV) block",
                    "criterion": "electrocardiography (EKG) abnormalities",
                    "requirements": [
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "abnormality type",
                            "expected_value": [
                                "2nd degree (type II) atrioventricular block",
                                "3rd degree atrioventricular block"
                            ]
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}